# OnCo record paper-keynote-189-407-tmb-jtocrr-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-keynote-189-407-tmb-jtocrr-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-keynote-189-407-tmb-jtocrr-2023" ;
  schema:name "Associations of tissue tumour mutational burden and mutational status with clinical outcomes with pembrolizumab plus chemotherapy versus chemotherapy for metastatic non-small-cell lung cancer"@en ;
  schema:description "In the two trials that established the treatment most patients with lung cancer actually receive, immunotherapy added to chemotherapy, the number of mutations in the tumour predicted nothing at all."@en ;
  schema:url <https://onco.cc/key-papers/paper-keynote-189-407-tmb-jtocrr-2023/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.jtocrr.2022.100431>, <https://pubmed.ncbi.nlm.nih.gov/36793385/> ;
  schema:sameAs <https://doi.org/10.1016/j.jtocrr.2022.100431> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Garassino MC, Gadgeel S, Novello S, et al." ;
  onco:related <https://onco.cc/biomarkers/tmb-high/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/tmb-testing/>, <https://onco.cc/technologies/wes-wgs/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/stk11/>, <https://onco.cc/targets/keap1/>, <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/cancer-immunity-cycle/> ;
  onco:terms <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/stk11-keap1/> ;
  onco:people <https://onco.cc/people/luis-paz-ares/> .